CAS 34233-69-7|Clozapine N-oxide
Introduction：Basic information about CAS 34233-69-7|Clozapine N-oxide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Clozapine N-oxide | ||
|---|---|---|---|
| CAS Number | 34233-69-7 | Molecular Weight | 342.823 |
| Density | 1.36g/cm3 | Boiling Point | 517.4ºC at 760mmHg |
| Molecular Formula | C18H19ClN4O | Melting Point | 190-248ºC |
| MSDS | ChineseUSA | Flash Point | 266.7ºC |
| Symbol | GHS06 | Signal Word | Danger |
Names
| Name | clozapine n-oxide |
|---|---|
| Synonym | More Synonyms |
Clozapine N-oxide BiologicalActivity
| Description | Clozapine N-oxide (CNO) is a major metabolite of the anti-psychotic drug clozapine. Clozapine N-oxide is a agonist for the chemogenetic Designer Receptors Exclusively Activated by Designer Drug (DREADD) system. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>5-HT ReceptorSignaling Pathways >>Neuronal Signaling >>5-HT ReceptorResearch Areas >>Neurological Disease |
| Target | DREADD[1] |
| In Vivo | After a single intraperitoneal (i.p.) injection of Clozapine N-oxide (1 mg/kg) into mice, Clozapine N-oxide (CNO) plasma levels peak at 15 min and are very low after 2 h. Acutely administered CNO can be metabolically converted to Clozapine in other species such as human and guinea-pig. The metabolites that may form after chronic administration of CNO to DREADD-expressing mice (or other species) have not been studied systematically. However, even if back-transformation to Clozapine occurs after chronic CNO administration, it should be noted that Clozapine is a more potent (by ~10-fold) DREADD agonist than CNO itself. Moreover, confounding biological effects of potential CNO metabolites can be easily identified by including both saline- and CNO-treated WT animals in a particular DREADD study. Despite the short plasma half-life of CNO in mice, the biological effects that have been described after acute treatment of DREADD-expressing experimental animals are usually much longer (6-10 h). One possibility is that CNO tends to accumulate in tissues, although other scenarios are also feasible[1]. Using a general pharmacokinetic model for the interconversion process, the mean total clearances of Clozapine and Clozapine N-oxide (CNO) are 28.45 L/hr and 45.30 L/hr, respectively[2]. |
| References | [1]. Wess J, et al. Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol Sci. 2013 Jul;34(7):385-92. [2]. Chang WH, et al. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 1998 Jul;22(5):723-39. |
Chemical & Physical Properties
| Density | 1.36g/cm3 |
|---|---|
| Boiling Point | 517.4ºC at 760mmHg |
| Melting Point | 190-248ºC |
| Molecular Formula | C18H19ClN4O |
| Molecular Weight | 342.823 |
| Flash Point | 266.7ºC |
| Exact Mass | 342.124725 |
| PSA | 57.06000 |
| LogP | 0.76 |
| Index of Refraction | 1.685 |
| InChIKey | OGUCZBIQSYYWEF-UHFFFAOYSA-N |
| SMILES | C[N+]1([O-])CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1 |
| Storage condition | 2-8℃ |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 245 mg/kg
- TOXIC EFFECTS :
- Behavioral - ataxia
- REFERENCE :
- CCCCAK Collection of Czechoslovak Chemical Communications. (Academic Press Inc. Ltd., 24-28 Oval Rd., London NW1 7DX, UK) V.1- 1929- Volume(issue)/page/year: 43,309,1978
Safety Information
| Symbol | GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H315-H319-H335 |
| Precautionary Statements | P261-P301 + P310-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | 22-36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | UN 2811 6.1/PG 3 |
| RTECS | HP1760000 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
Articles15
More Articles| Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks. J. Clin. Invest. 123(12) , 5342-50, (2013) The ability to map the functional connectivity of discrete cell types in the intact mammalian brain during behavior is crucial for advancing our understanding of brain function in normal and disease s... | |
| Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression. J. Clin. Invest. 123(12) , 5334-41, (2013) Negative affect is critical for conferring vulnerability to opiate addiction as reflected by the high comorbidity of opiate abuse with major depressive disorder (MDD). Rodent models implicate amygdala... | |
| Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. J. Med. Chem. 52 , 4266-76, (2009) The cardiac hERG K(+) channel constitutes a long-standing and expensive antitarget for the drug industry. From a study of the flexibility of hERG around its internal binding cavity, we have developed ... |
Synonyms
| 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e](1,4)diazepine N-oxide |
| 8-Chloro-11-(4-methyl-4-oxido-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine |
| 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-4-oxido-1-piperazinyl)- |
| Clozapine N-oxide |
| Clozapine (N-oxide) |
